№ files_lp_3_process_7_050126
File format: docx
Character count: 8897
File size: 27 KB
Academic research paper examining the diagnosis and treatment of Attention Deficit Hyperactivity Disorder and analyzing patterns, risks, and emergency department data related to nonmedical use of prescribed stimulant medications in the United States.
Author:
Shawnee Dixon
Title:
ADHD Medication
Course:
Drugs, Behavior and Modern Science
Type of document:
Research Paper
Date:
August 9, 2014
Subject:
Attention Deficit Hyperactivity Disorder and prescription stimulant abuse
Key topics:
ADHD diagnosis, stimulant medications, nonmedical use, emergency department visits, side effects
Institutions referenced:
National Institute of Mental Health (NIMH); Centers for Disease Control and Prevention (CDC); National Institute of Drug Abuse (NIH); Drug Abuse Warning Network (DAWN)
Medications discussed:
amphetamine; methylphenidate; atomoxetine; lisdexamfetamine dimesylate; dextroamphetamine; methamphetamine hydrochloride
Population focus:
Children and adolescents ages 3–17; individuals using prescription stimulants nonmedically
Geographical context:
United States
Sources cited:
NIMH (2013–2014); CDC (2013); NIH (2014); DAWN (2004, 2008); American Journal of Health-System Pharmacy (2014)
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / city:
United States
Topic:
Stimulant use disorder, clinical guidelines
Document Type:
Clinical Practice Guideline
Organization / Institution:
ASAM, AAAP
Author:
Not specified
Target Audience:
Healthcare professionals, addiction specialists
Effective Period:
Not specified
Approval Date:
2021
Date of Revisions:
Not specified
Year:
2023
Region / City:
Massachusetts
Topic:
Opioid Use Disorder, Medication Comparison
Document Type:
Clinical Guidelines
Organization / Institution:
Massachusetts Department of Public Health, Bureau of Health Care Safety & Quality
Author:
Massachusetts Department of Public Health
Target Audience:
Healthcare providers, Long-Term Care Facilities
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / city:
South East London
Topic:
Shared care prescribing for narcolepsy and idiopathic hypersomnia treatment
Document type:
Medical guideline
Organization / institution:
South East London Interface Prescribing Policy
Author:
Specialist clinicians, GP teams
Target audience:
Healthcare professionals, GPs, specialists
Period of validity:
Ongoing until updated
Approval date:
Not specified
Date of amendments:
Not specified
Jurisdiction:
Western Australia, Australia
Responsible authority:
Department of Health
Subject:
Prescribing of stimulant medicines
Document type:
Prescribing guidance / regulatory information
Target users:
Medical practitioners authorised to prescribe stimulant medicines
Approved conditions:
ADHD; Acquired brain injury; Depression; Narcolepsy; Binge eating disorder
Approved specialists:
Paediatrician; Neurologist; Paediatric neurologist; Psychiatrist; Child and adolescent psychiatrist; Rehabilitation physician; Paediatric rehabilitation physician; Respiratory and sleep physician; Thoracic medicine physician
Patient eligibility:
Patients within specified approved age criteria depending on prescriber specialisation
Minimum patient age:
4 years (for child-specialist prescribers)
Maximum stimulant doses:
Dexamfetamine up to 60 mg/day; Lisdexamfetamine up to 70 mg/day; Methylphenidate up to 120 mg/day; combination doses calculated as dexamfetamine equivalents
Prescription setting:
Clinical treatment of approved conditions
Regulatory requirement:
Notification to the Department of Health when commencing stimulant treatment or when specified patient or prescriber details change
Co-prescriber rules:
Co-prescribers must be medical practitioners practising in Western Australia and recorded in the notification
Review requirement:
Annual patient review by the primary stimulant prescriber
Contact service:
Schedule 8 Medicines Prescriber Information Service
Telehealth provision:
Interstate practitioners may prescribe via telehealth for Western Australian residents for prescriptions issued on or after 13 December 2023
Year:
No specific year mentioned
Region / City:
No specific region or city mentioned
Topic:
Cocaine use and its effects
Document Type:
Health and safety guide
Agency / Institution:
No specific agency or institution mentioned
Author:
No author specified
Target Audience:
General public, individuals seeking information on cocaine and its effects
Period of Validity:
No specific period mentioned
Approval Date:
No approval date mentioned
Date of Changes:
No date of changes mentioned
Year:
2017
Region / city:
United States
Topic:
Healthcare Plan, Education
Document Type:
Template
Organization:
National Association of School Nurses (NASN)
Author:
Arnold Zaiger, Will
Target Audience:
School Nurses, Healthcare Providers, Educators
Period of Action:
Ongoing, Specific to Students
Approval Date:
2017
Modification Date:
Not Provided
Year:
Not specified
Region / City:
Devon, England
Theme:
Adult ADHD Assessment and Treatment
Document Type:
Referral Form
Organization / Institution:
Harrow Health CIC
Author:
Not specified
Target Audience:
Healthcare professionals, GPs
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Service name:
Children’s Autism and ADHD Assessment Service (CAAAS)
Document type:
Parent/Carer information form
Purpose:
Referral support documentation
Target group:
Children and young people
Respondents:
Parents or carers with parental responsibility
Assessment areas:
Autism assessment; ADHD assessment
Health system:
NHS
Required submission:
Submitted with CAAAS Referral Form
Accepted file formats:
Word document; PDF; JPEG
Information scope:
Child demographics; family and household context; education setting; medical history; developmental profile; behaviour; attention; sensory processing; emotional regulation
Completion details:
Completed by parent or carer; date of completion required
Administrative note:
Attachment to referral documentation
Year:
2006-2007
Type of document:
Symptom checklist / assessment tool
Target audience:
Adults
Authors:
Adler et al., Kessler et al.
Purpose:
Screening for ADHD symptoms
Scope:
Clinical assessment
Scoring:
Part A (items 1-6), Part B (items 7-18)
Instructions:
Self-report, rate frequency of behaviors over past 6 months
Year:
2022
Region / City:
United Kingdom
Topic:
Mental Health, ADHD, Right to Choose
Document Type:
Letter
Author:
[Your Name]
Target Audience:
General Public, Healthcare Providers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Referral for ongoing ADHD treatment and management at College Health Service, Trinity College Dublin
Year:
2022
Region / city:
Dublin, Ireland
Topic:
ADHD, Clinical Care Pathway, University Health Services
Document type:
Referral Form
Institution:
College Health Service, Trinity College Dublin
Author:
Trinity College Health Service
Target audience:
Students with ADHD, Health Professionals
Period of validity:
Until further notice
Approval date:
2022
Amendment date:
Not specified
Year:
2026
Region / City:
United Kingdom
Subject:
ADHD treatment and medication management
Document Type:
Patient information letter
Organization / Institution:
NHS or affiliated healthcare practice
Author:
Specialist / GP practice
Target Audience:
Patient with ADHD
Medication:
Amber drugs for ADHD
Roles Defined:
Specialist, GP, Patient
Period of Care:
Ongoing
Requirements:
Annual review, adherence to shared care agreement
Note:
Year
Note:
Year
Contextual Description:
Referral form for adult ADHD assessment in North West London, detailing necessary patient and clinical information for the referral process.
Note:
Year
Region/City:
Hertfordshire
Topic:
Autism and ADHD Assessment
Document Type:
Questionnaire
Organization/Institution:
Hertfordshire Community NHS Trust, East and North Hertfordshire Community NHS Trust
Target Audience:
Parents, Carers, School Personnel
Year:
2023
Region / city:
Hertfordshire
Subject:
Autism and ADHD Assessment Referral
Document type:
Referral Form
Organ / institution:
East and North Hertfordshire NHS Trust, Hertfordshire Community NHS Trust
Author:
Not specified
Target audience:
Parents, carers, healthcare professionals
Effective period:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2026
Type of document:
Self-assessment questionnaire
Intended audience:
Adults
Topic:
ADHD symptoms
Completion instructions:
Rate yourself on each criterion over the past 6 months and return to GP
Format:
Checklist
Note:
Year
Theme:
ADHD, Assessment
Document Type:
Referral Form
Organization / Institution:
Alder Hey Children’s NHS Foundation Trust
Target Audience:
Healthcare professionals, Teachers, School staff, Parents
Year:
2026
Region / City:
Madison, WI
Subject:
Disability Assessment
Document Type:
Assessment Form
Organization / Institution:
McBurney Disability Resource Center, University of Wisconsin - Madison
Author:
McBurney Disability Resource Center
Target Audience:
Health professionals, academic staff, students with ADHD
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Revision:
Not specified
Year:
2024
Region / city:
United Kingdom
Topic:
ADHD, mental health, psychiatry
Document type:
Job description
Organization / institution:
Royal College of Psychiatrists
Author:
Royal College of Psychiatrists
Target audience:
Psychiatrists, mental health professionals
Period of validity:
April 2024 – June 2028
Approval date:
Not specified
Date of changes:
Not specified